

Male and Female					Male					Female							
Cancer Site	U.S. Rate (All Races)	N.E. Rate (All Races)	VT Rate (All Races)	VT Cases (per year)	Cancer Site	U.S. Rate (All Races)	N.E. Rate (All Races)	VT Rate (All Races)	VT Cases (per year)	Cancer Site	U.S. Rate (All Races)	N.E. Rate (All Races)	VT Rate (All Races)	VT Cases (per year)			
All Sites	431.6	462.3	452.6	▲▼	3,692	All Sites	468.2	498.3	472.3	▼	1,824	All Sites	407.6	440.8	442.0	▲	1,868
Lung and Bronchus	57.3	59.1	62.3	▲▲	527	Prostate	102.5	113.0	84.2	▼▼	361	Breast	124.4	132.9	131.9	▲	551
Melanoma of the Skin	21.7	21.4	35.8	▲▲	285	Lung and Bronchus	66.6	66.4	68.9	▼	269	Lung and Bronchus	50.2	53.9	57.1	▲	258
Colon and Rectum	38.1	38.7	35.1	▼▼	285	Melanoma of the Skin	27.8	27.1	44.0	▲▲	167	Uterus	26.5	31.2	34.4	▲▲	154
Urinary Bladder	19.9	23.5	22.9	▲	190	Urinary Bladder	34.7	40.9	37.9	▲	142	Colon and Rectum	33.5	34.0	33.1	▲	144
Non-Hodgkin Lymphoma	19.0	20.9	21.0	▲	168	Colon and Rectum	43.7	44.4	37.1	▼▼	141	Melanoma of the Skin	17.2	17.5	29.5	▲▲	118
Thyroid	14.5	19.5	14.4	▼	97	Non-Hodgkin Lymphoma	22.9	25.2	25.4	▲	94	Thyroid	21.4	28.5	20.4	▼	68
Kidney	16.4	16.3	14.3	▼▼	114	Kidney	22.2	22.5	19.5	▼▼	73	Non-Hodgkin Lymphoma	15.8	17.4	17.3	▲	74
Leukemia	13.6	14.5	12.4	▼	97	Oral Cavity/Throat	17.6	16.9	17.9	▲	72	Ovary	10.9	11.5	10.9	▲	45
Pancreas	12.2	13.1	12.3	▲	103	Leukemia	17.4	18.7	16.2	▼	58	Urinary Bladder	8.5	10.5	10.6	▲	48
Oral Cavity/Throat	11.6	11.3	11.7	▲	99	Pancreas	13.9	15.0	15.0	▲	58	Pancreas	10.7	11.5	10.1	▲	45
Brain/Nervous System	6.3	6.6	6.5	▲	47	Esophagus	7.7	8.3	10.6	▲▲	42	Kidney	11.4	11.0	9.8	▲	41
Esophagus	4.4	4.8	6.2	▲▲	54	Liver	12.0	12.3	8.5	▼▼	36	Leukemia	10.5	11.2	9.3	▼	39
Myeloma	6.6	7.0	5.7	▼▼	48	Thyroid	7.3	10.0	8.3	▼	29	Oral Cavity/Throat	6.4	6.6	6.2	▲	27
Liver	7.8	7.8	5.5	▼▼	47	Myeloma	8.2	8.7	7.7	▲	29	Brain/Nervous System	5.3	5.6	5.8	▲	22
Stomach	6.4	7.4	4.8	▼▼	39	Brain/Nervous System	7.4	7.8	7.2	▲	25	Cervix	7.5	7.0	4.1	▼▼	13
Larynx	3.2	3.3	3.4	▲	28	Stomach	8.8	10.3	7.0	▼▼	26	Myeloma	5.3	5.7	4.0	▼▼	19
Hodgkin Lymphoma	2.6	3.2	2.9	▲	19	Testis	5.6	6.1	6.5	▲	19	Stomach	4.5	5.2	3.0	▼▼	13
						Larynx	5.6	5.7	5.3	▲	21	Hodgkin Lymphoma	2.3	2.8	2.7	▲	9
						Hodgkin Lymphoma	3.0	3.5	3.0	▲	10	Liver	4.2	4.0	2.6	▼▼	11
											Esophagus	1.7	2.0	2.5	▲	11	
											Larynx	1.3	1.3	1.8	▲	7	

▲ Statistically higher than the U.S. rate. ▲ Statistically higher than the N.E. rate.  
▼ Statistically lower than the U.S. rate. ▼ Statistically lower than the N.E. rate.

**TECHNICAL NOTES:** All rates are age adjusted to the 2000 U.S. standard population and exclude basal cell and squamous cell skin cancers. Incidence rates exclude in situ carcinomas except urinary bladder. Incidence data were coded using the International Classification of Disease for Oncology (ICD-O) coding system. Vermont cases include Vermont residents only. The Vermont and U.S. incidence rates are based on the Vermont Cancer Registry, Vermont Department of Health (1994-2016) and the NPCR and SEER Incidence - U.S. Cancer Statistics Public Use Database, Nov 2018 submission (2001-2016). Northeast Region (N.E.) includes Connecticut, Maine, Massachusetts, New Hampshire, New York, Pennsylvania, Rhode Island, and Vermont. A reporting delay by Department of Veterans Affairs (VA) has resulted in incomplete reporting of VA hospital cases in 2011-2014, and 2016.

**COPYRIGHT INFORMATION:** All material in this report is in the public domain and may be reproduced or copied without permission. Citation as to source is appreciated. This document can be made available in other accessible formats.

**SUGGESTED CITATION:** Age Adjusted Cancer Incidence Rates, 2012-2016, Vermont Department of Health, Burlington, VT, 2019.

**ACKNOWLEDGEMENT:** This publication was supported by the Grant or Cooperative Agreement Number, NU58DP006322, funded by the Centers for Disease Control and Prevention. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention or the Department of Health and Human Services.

Male and Female					Male					Female				
Cancer Site	U.S. Rate (All Races)	N.E. Rate (All Races)	VT Rate (All Races)	VT Deaths (per year)	Cancer Site	U.S. Rate (All Races)	N.E. Rate (All Races)	VT Rate (All Races)	VT Deaths (per year)	Cancer Site	U.S. Rate (All Races)	N.E. Rate (All Races)	VT Rate (All Races)	VT Deaths (per year)
All Sites	161.0	157.9	164.6 ▲	165	All Sites	193.1	188.6	194.7	720	All Sites	137.7	136.9	142.3	642
Lung and Bronchus	41.9	40.4	43.7 ▲	366	Lung and Bronchus	51.6	49.1	50.4	193	Lung and Bronchus	34.4	34.0	38.5 ▲▲	174
Colon and Rectum	14.2	13.5	14.4	118	Prostate	19.2	18.5	19.9	67	Breast	20.6	19.8	18.2 ▼	81
Pancreas	11.0	11.3	11.0	91	Colon and Rectum	16.9	16.0	16.2	60	Colon and Rectum	11.9	11.7	12.7	58
Leukemia	6.5	6.4	6.2	50	Pancreas	12.6	13.0	12.3	46	Pancreas	9.6	9.9	9.9	44
Non-Hodgkin Lymphoma	5.6	5.6	6.0	48	Urinary Bladder	7.6	8.1	9.3 ▲	32	Ovary	7.0	7.1	7.0	31
Urinary Bladder	4.4	4.6	5.8 ▲▲	47	Leukemia	8.8	8.6	8.6	30	Uterus	4.7	5.3	4.8	22
Brain/Nervous System	4.4	4.2	5.4 ▲▲	42	Esophagus	7.1	7.6	8.3	33	Brain/Nervous System	3.6	3.4	4.8 ▲▲	20
Esophagus	4.0	4.3	4.8 ▲	41	Non-Hodgkin Lymphoma	7.3	7.2	7.8	28	Non-Hodgkin Lymphoma	4.4	4.3	4.6	20
Liver	6.5	6.1	4.2 ▼▼	37	Brain/Nervous System	5.4	5.2	6.2	23	Leukemia	4.9	4.8	4.3	20
Kidney	3.8	3.3	3.4	29	Liver	9.6	9.3	6.0 ▼▼	25	Urinary Bladder	2.1	2.3	3.5 ▲▲	15
Myeloma	3.3	3.1	3.3	28	Kidney	5.5	4.9	4.9	19	Liver	3.9	3.5	2.6 ▼	12
Oral Cavity/Throat	2.5	2.2	3.2 ▲▲	27	Oral Cavity/Throat	3.9	3.4	4.8 ▲	19	Myeloma	2.7	2.6	2.3	11
Melanoma of the Skin	2.5	2.3	2.6	22	Myeloma	4.2	3.9	4.6	17	Kidney	2.3	2.1	2.1	10
Stomach	3.1	3.2	2.4 ▼▼	20	Stomach	4.2	4.4	4.0	14	Esophagus	1.5	1.6	1.9	9
Larynx	1.0	1.0	1.0	9	Melanoma of the Skin	3.7	3.4	3.6	14	Oral Cavity/Throat	1.3	1.2	1.8 ▲	8
Thyroid	0.5	0.5	0.5	4	Larynx	1.8	1.8	1.7	7	Melanoma of the Skin	1.5	1.5	1.7	8
Hodgkin Lymphoma	0.3	0.3	0.3	2	Thyroid	0.5	0.5	0.6	2	Cervix Uteri	2.3	1.9	1.2 ▼▼	5
					Hodgkin Lymphoma	0.4	0.4	0.3	1	Stomach	2.3	2.2	1.1 ▼▼	5
					Testis	0.3	0.2	--	1	Larynx	0.4	0.4	0.5	2
										Thyroid	0.5	0.5	0.4	2
										Hodgkin Lymphoma	0.2	0.2	--	1

▲ Statistically higher than the U.S. rate.    ▲ Statistically higher than the N.E. rate.  
▼ Statistically lower than the U.S. rate.    ▼ Statistically lower than the N.E. rate.

**TECHNICAL NOTES:** All rates are age adjusted to the 2000 U.S. standard population and exclude basal cell and squamous cell skin cancers. Mortality data were coded using the International Classification of Disease Tenth Revision (ICD-10) coding system. Vermont deaths include Vermont residents only. -- Rates based on 5 or fewer deaths are not individually calculated. The Vermont and the U.S. mortality rates are based on the Vermont Vital Statistics System, Vermont Department of Health (1994-2016) and the SEER Program Mortality - Aggregated Total U.S. (1990-2016). Northeast Region (N.E.) includes Connecticut, Maine, Massachusetts, New Hampshire, New York, Pennsylvania, Rhode Island, and Vermont.

**COPYRIGHT INFORMATION:** All material in this report is in the public domain and may be reproduced or copied without permission. Citation as to source is appreciated. This document can be made available in other accessible formats.

**SUGGESTED CITATION:** Age Adjusted Cancer Mortality Rates, 2012-2016, Vermont Department of Health, Burlington, VT, 2019.

**ACKNOWLEDGEMENT:** This publication was supported by the Grant or Cooperative Agreement Number, NU58DP006322, funded by the Centers for Disease Control and Prevention. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention or the Department of Health and Human Services.